|Day's Range||34.76 - 34.87|
|52 Week Range||26.97 - 35.30|
|PE Ratio (TTM)||19.86|
|Dividend & Yield||0.74 (2.12%)|
|1y Target Est||N/A|
The chief executive of Smith & Nephew said on Friday that M&A was not at the top of his agenda, as the focus was on driving growth at the artificial knee and hip maker. A report in the Financial Times in March said Wright Medical , a U.S. company that specialise in surgical implants for extremities like feet and ankles, could be a takeover target for the British company. S&N Chief Executive Olivier Bohuon said M&A was "always on the agenda", and he had previously pointed to extremities as one of a number of areas of interest.
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 5.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Smith & Nephew Plc Here are 5 ETFs with the largest exposure to SNN-US. Comparing the performance and risk of Smith & Nephew Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)